Today marks the start of Blood Cancer Awareness Month. Our researchers are committed to work to understand the biology of blood cancer and harness this knowledge to identify new treatment strategies to help those affected.
In 2014, the charity Bloodwise awarded a 5-year programme grant to a team from Queen Mary University of London to support research to better understand the nature of the faulty genes responsible for an inherited/familial predisposition to MDS/AML.
Research published today in Cell Stem Cell has discovered a protein which drives an aggressive form of blood cancer, acute myeloid leukaemia (AML). Inactivation of this protein selectively compromises leukaemic cells while promoting normal blood cell functions.
